These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 31826069

  • 1. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V, Gateva A, Assyov Y, Alexiev A, Savov A, Yaneva N, Ivanova I, Ivanova-Boyanova R, Ivanova R, Vlahova Z, Mateva L, Kamenov Z.
    J Gastrointestin Liver Dis; 2019 Dec 09; 28(4):433-438. PubMed ID: 31826069
    [Abstract] [Full Text] [Related]

  • 2. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, Huang JF, Chen SC, Li SS, Chuang WL.
    Liver Int; 2011 Oct 09; 31(9):1326-31. PubMed ID: 21745282
    [Abstract] [Full Text] [Related]

  • 3. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, Hwang KB, Lee IH, Kim JI, Kong SW.
    Liver Int; 2015 Dec 09; 35(12):2537-46. PubMed ID: 26148225
    [Abstract] [Full Text] [Related]

  • 4. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.
    Hyysalo J, Gopalacharyulu P, Bian H, Hyötyläinen T, Leivonen M, Jaser N, Juuti A, Honka MJ, Nuutila P, Olkkonen VM, Oresic M, Yki-Järvinen H.
    Diabetes; 2014 Jan 09; 63(1):312-22. PubMed ID: 24009255
    [Abstract] [Full Text] [Related]

  • 5. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.
    Hepatology; 2016 Mar 09; 63(3):787-98. PubMed ID: 26605757
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals.
    Li J, Hua W, Ji C, Rui J, Zhao Y, Xie C, Shi B, Yang X.
    Pediatr Obes; 2020 Jun 09; 15(6):e12615. PubMed ID: 32020770
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease.
    Delik A, Akkız H, Dinçer S.
    Indian J Gastroenterol; 2020 Feb 09; 39(1):84-91. PubMed ID: 32333362
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY, Zheng KI, Pan XY, Ma HL, Zhu PW, Wu XX, Rios RS, Targher G, Byrne CD, Wang XD, Chen YP, Zheng MH.
    J Gastroenterol Hepatol; 2020 Jun 09; 35(6):1057-1064. PubMed ID: 31677195
    [Abstract] [Full Text] [Related]

  • 13. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT, Liu SS, Xie XJ, Liu Q, Xin YN, Xuan SY.
    Lipids Health Dis; 2020 Feb 24; 19(1):29. PubMed ID: 32093693
    [Abstract] [Full Text] [Related]

  • 14. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
    Lee SS, Byoun YS, Jeong SH, Woo BH, Jang ES, Kim JW, Kim HY.
    Dig Dis Sci; 2014 Dec 24; 59(12):2967-74. PubMed ID: 25069572
    [Abstract] [Full Text] [Related]

  • 15. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.
    Xia MF, Lin HD, Chen LY, Wu L, Ma H, Li Q, Aleteng Q, Hu Y, He WY, Gao J, Bian H, Li XY, Gao X.
    Diabetologia; 2019 Apr 24; 62(4):644-654. PubMed ID: 30673802
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
    Wijarnpreecha K, Scribani M, Raymond P, Harnois DM, Keaveny AP, Ahmed A, Kim D.
    J Gastroenterol Hepatol; 2020 Oct 24; 35(10):1789-1794. PubMed ID: 32220085
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.